Cell line · CVCL_0632
Papers51
1 to 20 of 51
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrin β6 expression in colorectal cancer cells promotes liver metastasis through enhanced adhesion to endothelial fibronectin. | Int J Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Clonal dispersal is associated with tumor heterogeneity and poor prognosis in colorectal cancer. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Direct Inhibition of RAS Reveals the Features of Oncogenic Signaling Driven by RAS G12 and Q61 Mutations. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The integrated stress response drives MET oncogene overexpression in cancers. | EMBO J | 2025 | Its Methods give the RRID and name the line | PubMed | |
Comparing in vitro cytotoxic drug sensitivity in colon and pancreatic cancer using 2D and 3D cell models: Contrasting viability and growth inhibition in clinically relevant dose and repeated drug cycles. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Exploiting a subtype-specific mitochondrial vulnerability for successful treatment of colorectal peritoneal metastases. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| HRS mediates tumor immune evasion by regulating proteostasis-associated interferon pathway activation. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Bromodomain protein BRD8 regulates cell cycle progression in colorectal cancer cells through a TIP60-independent regulation of the pre-RC complex. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. | Sci Signal | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Pan-cancer proteomic map of 949 human cell lines. | Cancer Cell | 2022 | Cellosaurus cites it | PubMed | |
| Analysis of RHOA mutations and their significance in the proliferation and transcriptome of digestive tract cancer cells. | Oncol Lett | 2021 | Cellosaurus cites it | PubMed | |
| Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. | J Exp Clin Cancer Res | 2021 | Its Methods give the RRID and name the line | PubMed | |
| Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer. | Cancers (Basel) | 2020 | Its Methods give the RRID and name the line | PubMed | |
| Quantitative Proteomics of the Cancer Cell Line Encyclopedia. | Cell | 2020 | Cellosaurus cites it | PubMed | |
| Next-generation characterization of the Cancer Cell Line Encyclopedia. | Nature | 2019 | Cellosaurus cites it | PubMed | |
| An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines. | Cancer Res | 2019 | Cellosaurus cites it | PubMed | |
| Differential Effector Engagement by Oncogenic KRAS. | Cell Rep | 2018 | Cellosaurus cites it | PubMed | |
| Pharmacoproteomic characterisation of human colon and rectal cancer. | Mol Syst Biol | 2017 | Cellosaurus cites it | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0632/papers